Khosla Impact, established in 2013, is an impact investment firm based in Menlo Park, California. It focuses on assisting high-impact entrepreneurs who develop products and services for the three billion people at the bottom of the world's economic pyramid. The firm invests in for-profit enterprises serving low-income individuals and small businesses in emerging markets, with a primary focus on South Asia. Khosla Impact encourages experimentation and supports entrepreneurs passionate about solving socio-economic challenges through technology and innovative business models.
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Vitara Biomedical
Series B in 2022
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.
Embrace Global
Series A in 2013
Embrace Innovations is a Bengaluru-based healthcare technology company focused on developing innovative and affordable medical devices for emerging markets. The company specializes in creating solutions to improve maternal and child health, notably through its flagship product, the Embrace Nest, a portable infant warmer designed for low birth-weight and premature babies. This device offers a cost-effective alternative to conventional incubators, priced at less than 1% of typical incubator solutions, aiming to reduce the high mortality rate among premature infants. In addition to its existing products, Embrace conducts research and development to foster new low-cost healthcare innovations, addressing critical needs in underserved communities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.